Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Zimmer

Showing results (141-150 of 218) with videos related to

Pageof 22
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2014
Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutationsLisa Zimmer, Fabrice Barlesi, Maria Martinez-Garcia, et al.
Journal for Immunotherapy of Cancer|November 15, 2019
Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center studyMarkus V Heppt, Teresa Amaral, Katharina C Kähler, et al.
The Lancet. Oncology|October 12, 2012
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trialGeorgina V Long, Uwe Trefzer, Michael A Davies, et al.
Lancet (London, England)|May 18, 2020
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trialLisa Zimmer, Elisabeth Livingstone, Jessica C Hassel, et al.
Cancers|June 2, 2021
Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma PatientsGeorg Lodde, Andrea Forschner, Jessica Hassel, et al.
European Journal of Cancer (Oxford, England : 1990)|March 14, 2024
Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanomaLea Jessica Albrecht, Florentia Dimitriou, Piyush Grover, et al.
The British Journal of Dermatology|February 20, 2026
Melanoma of unknown primary shows oncogenic pattern and clinical course of sun-exposed melanomaGeorg Lodde, Jonida Dollani, Wolfgang Galetzka, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 15, 2017
SF3B1 and BAP1 mutations in blue nevus-like melanomaKlaus G Griewank, Hansgeorg Müller, Louise A Jackett, et al.
Lancet (London, England)|September 13, 2022
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trialElisabeth Livingstone, Lisa Zimmer, Jessica C Hassel, et al.
Journal for Immunotherapy of Cancer|January 31, 2024
Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case seriesCatriona Harvey, Kazi J Nahar, Janet McKeown, et al.
Pageof 22

Showing results (141-150 of 218) with videos related to

Sort By:
Pageof 22
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2014
Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutationsLisa Zimmer, Fabrice Barlesi, Maria Martinez-Garcia, et al.
Journal for Immunotherapy of Cancer|November 15, 2019
Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center studyMarkus V Heppt, Teresa Amaral, Katharina C Kähler, et al.
The Lancet. Oncology|October 12, 2012
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trialGeorgina V Long, Uwe Trefzer, Michael A Davies, et al.
Lancet (London, England)|May 18, 2020
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trialLisa Zimmer, Elisabeth Livingstone, Jessica C Hassel, et al.
Cancers|June 2, 2021
Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma PatientsGeorg Lodde, Andrea Forschner, Jessica Hassel, et al.
European Journal of Cancer (Oxford, England : 1990)|March 14, 2024
Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanomaLea Jessica Albrecht, Florentia Dimitriou, Piyush Grover, et al.
The British Journal of Dermatology|February 20, 2026
Melanoma of unknown primary shows oncogenic pattern and clinical course of sun-exposed melanomaGeorg Lodde, Jonida Dollani, Wolfgang Galetzka, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 15, 2017
SF3B1 and BAP1 mutations in blue nevus-like melanomaKlaus G Griewank, Hansgeorg Müller, Louise A Jackett, et al.
Lancet (London, England)|September 13, 2022
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trialElisabeth Livingstone, Lisa Zimmer, Jessica C Hassel, et al.
Journal for Immunotherapy of Cancer|January 31, 2024
Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case seriesCatriona Harvey, Kazi J Nahar, Janet McKeown, et al.
Pageof 22